Abstract
Objectives: Data on abatacept (ABA) persistence in routine practice are limited. We aimed to study ABA persistence rates at 12 months, according to the date of initiation, and to analyze the factors associated with persistence at 12 months. Methods: We performed an observational, ambispective, multi-center study from January 2008 to July 2016, based on the French-RIC Network. We defined three groups of patients followed up for rheumatoid arthritis (RA), according to the date of initiation of ABA therapy: Group 1 (from 2007 to 31 July 2010: ABA indicated after anti-TNF failure); Group 2 (from 1 August 2010 to 31 March 2014: ABA indicated after conventional antirheumatic drugs failure); Group 3 (from 1 April 2014 to 1 July 2016: ABA available by the subcutaneous injection). Results: Among 517 patients who initiated ABA, drug persistence at 12 months was 68%. The only factor significantly associated with persistence rate at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation (odds ratio (OR) 0.6, 95% confidence interval 0.3–0.9; p = 0.0016). There was no significant difference in drug persistence according to date of initiation, the line of biological disease-modifying antirheumatic drugs (bDMARD) therapy or the route of administration. Conclusions: In routine practice, over time, ABA has come to be initiated earlier in the course of therapy for RA in France. Abatacept persistence is similar to that reported in the Orencia Rheumatoid Arthritis (ORA) registry, and does not differ according to the date of initiation. The only factor found to be associated with the persistence rate at 12 months was CRP < 10 mg/L at ABA initiation.
Highlights
Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease [1,2]
Our study evaluated ABA persistence in patients with rheumatoid arthritis (RA), in routine practice over a long period (2007–2016), with, respectively, 83%, 68% and 52% continuing treatment at 6, 12 and 24 months
The only factor found to be significantly associated with drug persistence at 12 months was C-reactive protein (CRP) < 10 mg/L at ABA initiation
Summary
Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease [1,2]. It can cause substantial handicap, and can be life-threatening [1]. Only TNF alpha inhibitors were available [3,4], but other drugs successively emerged, with different mechanisms of action and different therapeutic targets, such as anti-CD20 (rituximab) and a humanized (Tocilizumab) and the human (sarilumab) monoclonal antibody, recognizing the soluble and membrane-bound forms of IL-6 receptor [3,4]. ABA was recommended as third-line biologic therapy (after anti-TNF therapy failure). Since 1 August 2010, it can be prescribed as second-line biologic therapy (conventional antirheumatic drugs failure including MTX), and since 1 April 2014, has been available for subcutaneous administration
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
